The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.
So much hope for lupus, at last
Frédéric A. Houssiau, Brussels, Belgium
Falk Hiepe, Berlin, Germany
Why and how should we measure disease activity and damage in lupus?
Joy Feld and David Isenberg, London, United Kingdom
Which dose of steroids and which cytotoxics for severe lupus?
Pamela Lutalo et al., London, United Kingdom
Hydroxychloroquine: a multifaceted treatment in lupus
Nathalie Costedoat-Chalumeau et al., Paris, France
When biologics should be used in systemic lupus erythematosus?
Jacques-Eric Gottenberg et al., Strasbourg, France
Prevention and management of co-morbidities in SLE
Tanmayee Bichile and Michelle Petri, Baltimore, United States
What matters for lupus patients?
Gamal Chehab et al., Hamburg, Germany
Challenges for lupus management in emerging countries
Zoubida Tazi Mezalek and Wafa Bono, Rabat, Morocco